Asia Pacific SGLT2 Inhibitors Market Size is Anticipated to Reach US$ 3,972.35 Million Witnessing 8.1% CAGR by 2034

The growing population in nations with high diabetes existence, such as Japan, China, and South Korea, is driving the Asia Pacific SGLT2 inhibitors market.

NEW YORK CITY, NY, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- The Asia Pacific SGLT2 inhibitors market report assesses the competitive scenario of the market, examining all the established players and new market entrants.

The market for Asia Pacific SGLT2 inhibitors is on a growth trajectory. The market, valued at USD 1,824.71 million in 2024, is poised to reach USD 3,972.35 million by 2034. It is anticipated to register a CAGR of 8.1% from 2025 to 2034.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:
SGLT2 inhibitors are a kind of medicine that might lower blood sugar when one has type 2 diabetes. They escalate the aggregate of blood sugar which gets washed off when passing urine. If one has type 2 diabetes and has attempted all the alternate treatments, the doctor may indicate one to take SGLT2 inhibitors. They retain the kidneys from soaking up as much blood sugar to assist one getting rid of it.
SGLT2 inhibitors restrict the endeavor of proteins known as sodium-glucose cotransporter 2 that assist the kidneys in reabsorbing glucose from the blood. Growing consciousness amidst health experts and patients about the advantages of SGLT2 inhibitors in handling type 2 diabetes is impacting the Asia Pacific SGLT2 inhibitors market demand favourably.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-sglt2-inhibitors-market/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐊𝐞𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• The Asia Pacific SGLT2 inhibitors market size was valued at USD 1,824.71 million in 2024 and is projected to grow to USD 3,972.35 million by 2034.
• The growing elderly population is more susceptible to type 2 diabetes fuels the need for SGLT2 inhibitors in Asia Pacific.
• The market segmentation is primarily based on indication, drug, distribution channel, and country.
• The study provides market insights into China, Japan, India, Malaysia, South Korea, Indonesia, Australia, Vietnam and the Rest of Asia Pacific.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐢𝐧 𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐒𝐆𝐋𝐓𝟐 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭:
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
• Lexicon Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Sanofi
• Pfizer Inc.
• Lupin
• Cipla Limited

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:
The Asia Pacific SGLT2 inhibitors market is portrayed by aggressiveness. Spearheading market contenders are funding massively in research and development so as to augment their product line which will assist the market to grow even more. Market contenders are also shouldering an assortment of tactical ventures to augment their regional footprint with crucial market advancements involving contemporary product instigations, constitutional consensus, mergers and acquisitions, elevated funding, and association with other firms.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-sglt2-inhibitors-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐇𝐞𝐫𝐞 𝐚𝐫𝐞 𝐬𝐨𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐚𝐣𝐨𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬:

• In January 2024, Jilin Huisheng Biopharmaceutical Co, Ltd. acquired consent from the China NMPA for the marketing of Ganagliflozin Proline Tablets.

• In February 2023, Zydus Lifesciences Limited obtained consent from the United States Food and Drug Administration (USFDA) to materialize Canagliflozin tablets.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬:
• Progressive Infrastructure Facilities: Asia Pacific is encountering notable growth in healthcare with progressive framework facilities, which are essential for the speedy recognition and productive handling of diabetes, fueling the Asia Pacific SGLT2 inhibitors market growth.

• Growing Prevalence of Type 2 Diabetes: The growing existence of type 2 diabetes covering Asia Pacific, influenced by urbanization, lifestyle alteration, and genetic tendencies, is pushing the demand for productive diabetes handling solutions such as SGLT2 inhibitors.

• Speedy Urbanization: Speedy urbanization in the Asia Pacific has caused notable alterations in dietary patterns, with people moving from conventional, whole-food diets to elevated-calorie processed food. This shift towards processed foods, together with a more desk-bound lifestyle, has ignited the rise in obesity, a prominent probability element for the advancement of type 2 diabetes.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
India is anticipated to witness a significant CAGR from 2025 to 2034. The country’s robust growth is due to its burgeoning pharmaceutical sector, which is the largest and booming worldwide and has encouraged invention through association between home and foreign firms.
China accounted for the largest share of the Asia Pacific SGLT2 inhibitors market in 2024. This is extensively due to the elevated existence of type 2 diabetes pushed by speedy economic growth, urbanization, and linked lifestyle alterations.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐛𝐞𝐟𝐨𝐫𝐞 𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-sglt2-inhibitors-market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:

By Indication Outlook:
• Cardiovascular
• Chronic Kidney Disease (CKD)
• Type 2 Diabetes
• Others

By Drug Outlook:
• Farxiga (Dapagliflozin)
• Inpefa (Sotagliflozin)
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Qtern (Dapagliflozin/Saxagliptin)
• Other SGLT2 Inhibitors

By Distribution Channel Outlook:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Country Outlook:
• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific

𝐅𝐀𝐐𝐬:
How much is the Asia Pacific SGLT2 inhibitors market growth?
The market size was valued at USD 1,824.71 million in 2024 and is anticipated to reach USD 3,972.35 million by 2034.

Which country held the largest Asia Pacific SGLT2 inhibitors market share?
China had the largest market share in 2024.

Based on indication, which segment led the market in 2024?
The type 2 diabetes segment dominated the market in 2024.

What is the growth rate of the market?
The market is projected to exhibit a CAGR of 8.1% from 2025 to 2034.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐏𝐌𝐑'𝐬 𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐒𝐆𝐋𝐓𝟐 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐟𝐫𝐨𝐦 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:
Asia Pacific SGLT2 inhibitors industry is expected to reach USD 3,972.35 million by 2034, exhibiting a CAGR of 8.1% from 2025 to 2034.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
In Vitro Diagnostics Quality Control Market:
https://www.polarismarketresearch.com/industry-analysis/in-vitro-diagnostics-quality-control-market

Needle Holder Market:
https://www.polarismarketresearch.com/industry-analysis/needle-holder-market

Injection Pen Market:
https://www.polarismarketresearch.com/industry-analysis/injection-pen-market

Nonmydriatic Fundus Cameras Market:
https://www.polarismarketresearch.com/industry-analysis/nonmydriatic-fundus-cameras-market

Digital X-Ray Market:
https://www.polarismarketresearch.com/industry-analysis/digital-x-ray-market

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.

Likhil G
Polaris Market Research and Consulting
+1 929-297-9727
sales@polarismarketresearch.com
Visit us on social media:
Facebook
X
LinkedIn